InvestSMART

BCAL Diagnostics Limited (ASX: BDX) - Announcements

- Current share price for BDX : $0.085

ASX company news and announcements for BCAL Diagnostics Limited (BDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BCAL Diagnostics Limited (BDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BCAL Diagnostics Limited (BDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BCAL Diagnostics Limited (BDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Validation Agreement Signed with Sonic USA, for Breastest V2 28 May 2026 8:25AM $0.080 $0.085 risen by 6.25%
$31 BCAL Launches Early Detection Cancer Platform 19 May 2026 10:09AM $0.077 $0.085 risen by 10.39%
$31 BCAL Appoints Anne-Louise Arnett as Chief Executive Officer 11 May 2026 8:23AM $0.074 $0.085 risen by 14.86%
$31 Quarterly Activities/Appendix 4C Cash Flow Report 22 Apr 2026 8:50AM $0.090 $0.085 fallen by 5.56%
$31 BCAL Submits MSAC Application for Avantect Pancreatic Test 31 Mar 2026 9:11AM $0.092 $0.085 fallen by 7.61%
$31 BCAL Accelerates Rollout of Avantect Early Detection Tests 26 Mar 2026 9:19AM $0.095 $0.085 fallen by 10.53%
$31 Change of Director's Interest Notice 20 Mar 2026 5:08PM $0.092 $0.085 fallen by 7.61%
$31 Change of Director's Interest Notice 19 Mar 2026 5:21PM $0.098 $0.085 fallen by 13.27%
$31 Change of Director's Interest Notice 17 Mar 2026 3:31PM $0.095 $0.085 fallen by 10.53%
$31 Cleansing Notice 6 Mar 2026 3:21PM $0.120 $0.085 fallen by 29.17%
$31 Application for quotation of securities - BDX 6 Mar 2026 3:14PM $0.120 $0.085 fallen by 29.17%
$31 Change of Director's Interest Notice 20 Feb 2026 7:26PM $0.125 $0.085 fallen by 32%
$31 BCAL Half Year Results Presentation December 2025 18 Feb 2026 11:33AM $0.115 $0.085 fallen by 26.09%
$31 Half Yearly Report and Accounts 17 Feb 2026 7:47PM $0.120 $0.085 fallen by 29.17%
$31 BCAL Webinar Review Half Year Results 18 February 11am AEDT 13 Feb 2026 10:13AM $0.120 $0.085 fallen by 29.17%
$31 Shareholder Update 5 Feb 2026 8:24AM $0.115 $0.085 fallen by 26.09%
$31 Initial Director's Interest Notice 3 Feb 2026 8:45AM $0.120 $0.085 fallen by 29.17%
$31 Mr Mark McConnell Appointed to the Board 27 Jan 2026 8:51AM $0.125 $0.085 fallen by 32%
$31 Quarterly Activities/Appendix 4C Cash Flow Report 21 Jan 2026 8:53AM $0.125 $0.085 fallen by 32%
$31 Change in substantial holding 19 Jan 2026 3:23PM $0.125 $0.085 fallen by 32%
$31 Application for quotation of securities - BDX 15 Dec 2025 8:19AM $0.100 $0.085 fallen by 15%
$31 Pancreatic and Ovarian Cancer Early Detection Blood Testing 9 Dec 2025 8:23AM $0.100 $0.085 fallen by 15%
$31 Ethics Approval to Establish BREASTEST Registry 3 Dec 2025 8:28AM $0.110 $0.085 fallen by 22.73%
$31 Results of Meeting 28 Nov 2025 1:17PM $0.105 $0.085 fallen by 19.05%
$31 BCAL AGM Presentation 28 Nov 2025 10:47AM $0.093 $0.085 fallen by 8.60%

26 - 50 of 274 results

Page 2 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.